Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group Plc LSE:DEMG London Ordinary Share GB0059337583 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.35 58,724 01:00:00
Bid Price Offer Price High Price Low Price Open Price
1.20 1.50 1.35 1.35 1.35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 4.26 -0.21 -0.03 7
Last Trade Time Trade Type Trade Size Trade Price Currency
08:26:25 O 58,724 1.3655 GBX

Deltex Medical (DEMG) Latest News

More Deltex Medical News
Deltex Medical Takeover Rumours

Deltex Medical (DEMG) Discussions and Chat

Deltex Medical Forums and Chat

Date Time Title Posts
23/9/202007:40Deltex Medical - a British success story!11,145
21/9/202009:16Deltex Medical-Optimal Growth Stock10,013
05/6/202014:27Deltex Medical - winner or doomed to fail? 410
19/6/201812:15Deltex Medical interview with new CEO1
06/6/201821:52Interview with Deltex Medical Group 1

Add a New Thread

Deltex Medical (DEMG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:26:251.3758,724801.88O
View all Deltex Medical trades in real-time

Deltex Medical (DEMG) Top Chat Posts

DateSubject
25/9/2020
09:20
Deltex Medical Daily Update: Deltex Medical Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker DEMG. The last closing price for Deltex Medical was 1.35p.
Deltex Medical Group Plc has a 4 week average price of 1.35p and a 12 week average price of 1.25p.
The 1 year high share price is 2.75p while the 1 year low share price is currently 0.90p.
There are currently 524,464,064 shares in issue and the average daily traded volume is 259,686 shares. The market capitalisation of Deltex Medical Group Plc is £7,080,264.86.
19/7/2020
22:18
buywell3: ==== buywell takes a look at one of DEMG major shareholders ===== ===== Michael Stubbs first announced on Feb 5th 2019 that he had acquired ===== 15,950,000 shares in DEMG --- 3.18% Though the date , see note --- vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect. This date was months earlier on ---- 3rd December 2018 buywell has NEVER seen such a long notification RNS delay The above chart starts 17th Sept 2018 and ends 3rd Dec 2018 ( Date threshold ie 3% was crossed ) The place of completion or address ------ Place of completion ---- Gloucester buywell thinks it logical that Michael Stubbs from Gloucester bought just under 3% earlier around Sept when the price bombed eg around 1.3p the current share price. Remember when looking at volumes on the chart a volume of 15M = half sells and half buys ie 7.5M of each dyor
20/5/2020
13:18
gbenson1: How many shares need to be bought/traded before the mms increase the share price? Even when they do they probably won't move the bid!!
07/5/2020
10:03
gbenson1: Share price has retraced some 40% from recent highs, it would be nice if the company could give a post AR /Covid-19 update!
30/4/2020
20:18
nobbygnome: Cheetah a private company who have an inferior technolgy were taken over for the equivalent DEMG price of 10p. A big acquirer like Edwards would value the technology on a multiple of turnover because they know with a bit of marketing spend they could massively increase that turnover. DEMG have spent years building an evidence base which shows their technology works the best in the field. That has a big value to a company like Edwards. LID most definitely do not hav ethat evidence based and their market cap is well above DEMG at present. Oh and their technology is not proven to work in surgery.... DEMG is still cheap at this level. I was buying this afternoon when the price pulled back!
30/4/2020
17:44
t0pgrader: According to Arden, Demg's P/E forecast is: Y/E Dec 2020 P/E 100 Y/E Dec 2021 P/E 36 Only a takeover could sustain such a frothy share price https://research.arden-partners.com//view_repos/_c2abac3b-95ba-494f-b75b-6f4d7d97c494.pdf
29/4/2020
22:44
bmnsa: Disappointing share price reaction today,hoping for better tomorrow.
28/4/2020
12:55
gbenson1: mms definitely want your shares, currently 2.025 to sell way above the quoted 1.90 bid and only .025 from the median/current share price.
12/3/2020
00:34
buywell3: Wonder if LID might offer 1 LID for 6 DEMG ? Would be generous with hindsight if the new NOMAD puts a decent note out that send LID back to 10p with a forward target of 20p plus ------------ RNS and a new LID NOMAD , N+1 Singer --------------- It is to be hoped that the new NOMAD , N+1 Singer will produce some decent new research notes to promote LiDCO and to show how their HUP initiatives are bearing fruit. A new forward looking LiDCO share price prediction will IMO follow to reflect recent acquisitions of smaller companies involved in the manufacture of Hemodynamic Monitors. Companies it should be noted that did not currently supply the NHS with 60% of its Hemodynamic Monitors as LiDCO does, plus recent increased HUP sales and sales into China. Companies that did not have a China based Hemodynamic Monitor manufacturing facility , as LiDCO has. htTps://www.investegate.co.uk/lidco-group-plc--lid-/rns/latest-monitor-launched-in-china/201911050700052267S/ Covid -19 developments that buywell has eluded to in recent posts will one would think factor quite highly in such. ----------- The WHO has just declared Covid -19 a pandemic ----------- The new chancellor of the exchequer in the budget announcement, regarding the coming fight against Covid-19 has just announced : The NHS will get 1) Whatever it needs 2) Whatever it costs buywell recent posts has stated where this fight to save lives will take place , the battlefield will be in Hospital Intensive Care Units ( ICU's). This is where around 15% of patients that develop viral pneumonia , then circa 5% that develop septic shock and sepsis following on from viral pneumonia , will have to be treated. buywell believes the monies to buy Hmodynamic Monitoring equipment , which LiDCO has clinically showed to save lives in such circumstances , has been paid for by anaesthetists. Stats improvements in lives saved, reduction in length of stay (LOS) , and reduced complications stats , have to the best of my knowledge NOT been shown against the anaesthetists who bought and paid for the Hemodynamic Monitors but have shown improved stats for other parts of the Hospital. The NHS as we all know is now very stats driven In Italy ICU's are struggling to cope with the Covid-19 burden being placed upon them Germany has just announced it expects circa 60% of its population to acquire Covid-19 The junior minister for health Narine Dorries has just acquired it herself htTps://www.smh.com.au/world/europe/uk-health-minister-nadine-dorries-diagnosed-with-coronavirus-20200311-p548wl.html buywell expects many other members of the government will also acquire it, some of the elder ones will get treated in ICU's. The time is therefore ripe for the NHS to purchase Hemodynamic Monitoring equipment in those Hospitals and Trusts where monies have been too tight to allow its purchase, the chancellor has just stated '' whatever the cost '' LiDCO buywell thinks , will be revisiting ALL Hospitals and Trusts to explain once more the merits of using their equipment via their HUP deal ( costs spread over 3 to 5 years) , with a list showing all those 25% of NHS Hospitals that have to date now switched to such a deal (HUP) with an NHS contact name , so that they can be referenced to gain relevant data regarding the NHS benefits to patients from the NHS horses mouth. Important: The use of Hemodynamic Monitoring in sepsis and septic shock has very clearly been clinically demonstrated hTtp://www.lidco.com/case-study/sepsis/ hTtp://www.lidco.com/education/how-to-save-lives-in-sepsis/ Covid-19 will at some point have a vaccine made to fight against it, maybe 12 to 18 months away. Other Coronaviruses are on the way however which will have similar symptoms , viral pneumonia , septic shock and sepsis. buywell's point being : The purchase of Hemodynamic Monitoring units now to fight Covid-19 will NOT be wasted once it goes away. IMO LiDCO could receive many orders from around the world as death rates look set to rise due to a lack of ICU hospital beds and a lack of Hemodynamic Monitors. dyor
28/11/2019
22:50
arf dysg: It's not a share, it's a company. Alternatively, if you're asking "how is the share price doing?" then the answer is blindingly obvious. If you can't see the share-price chart, then how will you see these answers, which tell you to look at the share price chart?
23/8/2019
12:49
buywell3: A subscription raising £1.125 million by way of new convertible loan notes due 2019 ("Loan Notes") with an interest rate of 8% and a conversion price of 6 pence. The Loan Notes are repayable in full on the third anniversary of their date of issue although they may be prepaid in whole or in part at the Company's discretion at any time. Loan Notes The Company intends to raise £1.125 million by the issue of the Loan Notes. Of these, Imperialise Limited (a company associated with Nigel Keen, non-executive Chairman of the Company), has agreed to subscribe for £500,000 nominal amount of the Loan Notes. The Loan Notes are unsecured and interest is payable at 8% per annum. The Loan Notes are repayable in full on the third anniversary of their date of issue although they may be prepaid in whole or in part at the Company's discretion at any time. The Loan Notes are convertible at any time up until repayment into 18,750,000 ordinary shares at the effective price of 6p, being a premium of 30 per cent. over the share price at close of business on 2 February 2016 and a premium of 50 per cent. over the Issue Price. The Company can also enforce conversion if the ordinary share price is equal to or exceeds 18p for any period of 30 consecutive days. If the Company elects to prepay all or any of the Loan Notes, it will issue to the note holders warrants to subscribe for ordinary shares at 6 pence per share (at the rate of 5,000 warrants for every £300 nominal of Loan Notes repaid (and pro rata for any greater or lesser amount repaid)). Such warrants will be exercisable within the same period as corresponds to the conversion rights previously attaching to the Loan Notes prepaid.
Deltex Medical share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DEMG
Deltex Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200925 13:50:12